---
layout: post
title: "【图解季报】恒瑞医药：2022年一季度归母净利润同比下降17.3%，小于营收降幅"
date: 2022-04-22 19:33:48 +0800
categories: dongfangcaifuChoiceshuju
tags: 东方财富Choice数据新闻
---
<p>恒瑞医药于2022年4月23日披露一季报，公司2022年一季度实现营业总收入54.8亿，同比下降20.9%；实现归母净利润12.4亿，同比下降17.4%；每股收益为0.19元。</p><img id="image7" class="autoimg" src="https://dfscdn.dfcfw.com/download/D277FF2E9C132E3D618A1F43B1E7322558_w800h400.jpg" alt=""><p style="color:#61768C;font-size:0.9em;"></p><img id="image9" class="autoimg" src="https://dfscdn.dfcfw.com/download/D23584EFD23A7964CF355DFC34D0EB8684_w800h400.jpg" alt=""><p><strong>期间费用为32.5亿，营业成本为8.6亿</strong></p><p>公司2022一季度营业成本8.6亿，同比下降6.1%，低于营业收入20.9%的下降速度，毛利率下降2.5%。期间费用率为59.3%，较去年下降1.2%。</p><img id="image12" class="autoimg" src="https://dfscdn.dfcfw.com/download/D27DA351CF39F42A97EE951F92414041D2_w800h400.jpg" alt=""><p style="font-weight:bold;"></p><p style="margin: 10px 0; color: #999">免责声明：本文基于大数据生产，仅供参考，不构成任何投资建议，据此操作风险自担。</p><style>.autoimg {display: block;border: 0;max-width: 100%;margin: 0 auto;} .tbl {border-collapse: collapse;border-spacing: 0;text-align: center;width: 100% !important;} .tbl tr th, .tbl tr td {border: 1px solid #d8e6ff;padding: 5px;text-align: center;} .tbl tr th {color: #fff;background-color: #1c65b0;vertical-align: middle;} .tbl tr td {color: #000;background-color: #fff;} .imgtitle {text-indent: 0;text-align: center;color: #2395F1;} .autosrc {color: #999;display: block;text-align: center;margin-bottom: 5px;}</style>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202204222354364829>

[返回东方财富Choice数据新闻](//finews.withounder.com/category/dongfangcaifuChoiceshuju.html)｜[返回首页](//finews.withounder.com/)